News
Off-Label Use of JAK Inhibitors in Orphan Diseases and Other Conditions?
When should you consider off-label use of JAKi?
Novel TYK2 inhibitor Zasocitinib
Similar to JAKs, TYK2 is an important mediator of innate and adaptive immune activation. Unlike JAKs, however, TYK2 is thought to play a minimal role in other pathways, such as metabolic and hematopoietic axes. Therefore, it is hypothesized that TYK2-targeted agents could be effective in rheumatic disease, with a potential for less off-target adverse effects. Zasocitinib is a new, oral TYK2 inhibitor generated using artificial intelligence-assisted compound design.
Diagnostic Delays in PsA
Despite the remarkable expansion of the therapeutic armamentarium for psoriatic arthritis (PsA), the MONITOR-PsA study highlights a persistent and critical issue: delays in diagnosis. The study findings are stark, with about 25% of patients having erosions at diagnosis.
Standardizing Still’s Disease Research: Global Data Harmonization Needed
A recent study presented at #ACR24 convergence highlights significant gaps and inconsistencies in the research of systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD).
Why should rheumatologists care about aging?
The global population is aging and none of our rheumatic diseases are immune to the impact of the complexities and so-called “geriatric syndromes”, including sarcopenia, frailty, falls and cognitive impairment, associated with the aging process. Whilst we are increasingly aware of these syndromes, it is sometimes overwhelming to consider just how we may incorporate the unique needs of our older patients into our already busy clinical practice – or perhaps until now we were unsure of their significance and relevance. Why should we care about aging?
RA-ILD in the Spotlight at ACR 2024
Over the past 5 years, there has been growing interest in RA-ILD due to its relative prevalence and severity. This seems to be one of the few RA outcomes not improving much, even with the advent of expanded treatment options. There is also a shocking lack of trial data. This year, there were two oral sessions dedicated to RA-ILD, one of which even the overflow room was standing room only, in addition to many posters.
What Lies Beneath: Understanding Nailfold Capillaroscopy
Capillaroscopy is a non-invasive imaging technique used for the in vivo assessment of the microcirculation. kin capillaries at the nailfold are evaluated because the fingers are involved in pathological processes such as Raynaud’s phenomenon. Several abstracts and sessions on nailfold capillaroscopy were presented during ACR24.
Maximizing DMARDs to Strive for Steroid-Free Remission in RA
In 1950, three scientists were awarded the Nobel Prize for their groundbreaking discovery of steroids, heralded at the time as a "miracle cure" for rheumatoid arthritis (RA).
Novel and Emerging Therapies in Psoriatic Arthritis
Recent advancements in targeted therapies, including selective inhibitors of key inflammatory pathways, offer promising outcomes for patients with active psoriatic arthritis (PsA). At ACR 2024, there have been further developments in novel therapies in PsA.
ICYMI: Taking AI Out of AutoImmunity: Predicting disease before it develops
the predictive value of a positive ANA test—especially in the absence of other clinical symptoms—remains a challenge. A positive test often leads to further testing, yet it does not necessarily indicate whether a patient truly has an underlying autoimmune disease. The development of AI and machine learning algorithms presents an opportunity to interpret autoantibody tests and predict autoimmune diseases. Here are three studies looking at this issue.